Condition category
Haematological Disorders
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
This is a study of patients admitted to Intensive Care Units (ICUs) who are not bleeding, but are traditionally considered to be at the greatest risk of bleeding because they have a prolonged Prothrombin Time (PT). Prothrombin Time is the time it takes for your blood to clot and is currently the test used to measure the blood's ability to prevent bleeds, but there are newer tests that may be more effective. Transfusions of fresh frozen plasma are often given to correct prolonged PTs, but more evidence is needed to see if this is necessary. The results of this study will provide a better understanding of the relationship between the traditional blood test Prothrombin Time (PT), and the new tests, Rotational Thromboelastography (ROTEM), Thrombin Generation (TG) and Thromboelastography (TEG), that measure the body’s ability to prevent bleeds. This will provide an insight into the limitations of our traditional test for assessing someone’s risk of bleeding, and whether it should continue to be used, or whether the new tests should be used. By looking at whether fresh frozen plasma improves the results of the traditional and new tests, we will be better informed about whether or when to give it.

Who can participate?
If you are aged 18 and over and admitted to a participating Intensive Care Unit with a sufficiently prolonged PT, and are not actively bleeding or on treatment dose blood thinners.

What does the study involve?
Anonymous information about why participants are in intensive care will be collected, blood samples will be taken and the results of routine blood tests will be recorded daily. If participants need a transfusion, blood samples will be taken before and after the transfusion is given. Participants will take part in the study until day 5 of ICU admission or discharge from the ICU, whichever occurs first.

What are the possible benefits and risks of participating?
There are no direct benefits of taking part in the trial, but the results of this study will help inform how we measure the risk of bleeding when patients are admitted to an intensive care unit (ICU) and how we manage it.

Where is the study run from?
Addenbrooke’s Hospital, Cambridge is the lead centre. Other centres that may take part are:
1. John Radcliffe Hospital, Oxford
2. Royal London Hospital, London
3. St Thomas’ Hospital, London
4. Edinburgh Royal Infirmary, Edinburgh

When is the study starting and how long is it expected to run for?
The study started in May 2012 and will run for 12 months.

Who is funding the study?
CSL Behring, UK.

Who is the main contact?
Mrs Fiona Goddard

Trial website

Contact information



Primary contact

Dr Simon Stanworth


Contact details

National Health Service Blood and Transplant (NHS BT)
Oxford Radcliffe Hospitals
John Radcliffe Hospital
United Kingdom
+44 (0)186 538 7976

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

A prospective cross-sectional observational study of haemostatic testing in patients admitted to adult critical care with prolongation of prothrombin time without clinical bleeding



Study hypothesis

Prolongation of prothrombin time (PT) does not correlate well with an individual’s coagulation potential, bleeding or thrombosis, and the global clotting tests Rotational Thromboelastography (ROTEM), Thrombin Generation (TG) and Thromboelastography (TEG) might be better predictors of bleeding and thrombosis. Studies evaluating the optimal management of coagulopathy in critically ill patients need to be based around better validated tests of haemostasis. Future clinical studies may then evaluate restricted, or targeted use of replacement therapies such as Fresh Frozen Plasma (FFP) or small volume prohaemostatic drugs such as Packed Cell Concentrate (PCC).

Ethics approval

Oxford Research Ethics Committee, 28 October 2011, ref:11/SC/0429

Study design

Multicentre prospective cross sectional non randomised observational study

Primary study design


Secondary study design

Non randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Coagulopathy in intensive care


Blood will be taken on enrolment, before and after Fresh Frozen Plasma transfusion or at the end of the study if no transfusion is given. The majority of patients will have central venous access or peripherally inserted central cannulae (PICC) as this is part of the routine management of a patient requiring intensive care. Where possible, samples will be taken from a central line or Peripherally Inserted Central Cannula (PICC) line as this is a painless proceedure, where neither is available, or functioning, samples will be collected by venepuncture. Venepuncture is associated with a sting on insertion of the needle, however the majority of patients on ITU will be receiving pain relief and venepuncture is routinely undertaken without pain relief. The initial blood samples required for the study will total no more than 15ml of blood. This is minimal compared with the total volume of blood in the body, which is 5 litres and should not have a negative clinical effect. The further samples required before and after a FFP transfusion, or at the end of the study, will again be no more than 15ml.

Intervention type



Not Applicable

Drug names

Primary outcome measures

Haemostasis will be measured using traditional coagulation tests [ prothrombin time (PT), activated partial thromboplastin time (APTT), platelets, fibrinogen) and the new whole blood techniques of assessing clot formation and breakdown TG, Thrombelastography (TEG) and thromboelastometry (ROTEM).

Clotting factor levels, vWF levels, antithrombin, proteins c and s levels will be measured, in cases where there is a disproportionate difference between PT and the newer techniques of measuring coagulopathy.

Secondary outcome measures

1. The effect of transfusing FFP will be measured using traditional coagulation tests (PT, APTT, platelets, fibrinogen) and the new whole blood techniques of assessing clot formation and breakdown TG, TEG and ROTEM.
2. The number and severity of clinically significant bleeds will be recorded using a Bleeding Assessment Form

Overall trial start date


Overall trial end date


Reason abandoned


Participant inclusion criteria

1. Admission to a general intensive care unit
2. Prolongation of the PT time by more than 3 seconds beyond the upper limit of the normal range for local hospital within 48 hours of admission

Participant type


Age group




Target number of participants


Participant exclusion criteria

1. No evidence of active clinical bleeding at the time of enrolment (for example active blood loss through post-operative drains, or clinically significant bleeding, defined as an estimated total cumulative blood loss > 300ml)
2. Warfarin therapy or other treatment dose anticoagulant therapy at the time of enrolment

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

National Health Service Blood and Transplant (NHS BT)
United Kingdom

Sponsor information


NHS Blood and Transplant (NHSBT) (UK)

Sponsor details

c/o Prof Marion Scott
Oak House
Reeds Crescent
WD24 4QN
United Kingdom
+44 (0)192 348 6800

Sponsor type




Funder type


Funder name

CSL Behring (UK)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes